Astonea Labs Ltd
Incorporated in 2017, Astonea Labs Ltd. is engaged in contract manufacturing of pharmaceutical and cosmetic products for companies[1]
- Market Cap ₹ 340 Cr.
- Current Price ₹ 323
- High / Low ₹ 369 / 118
- Stock P/E 75.1
- Book Value ₹ 54.4
- Dividend Yield 0.00 %
- ROCE 10.5 %
- ROE 12.0 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 5.94 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Working capital days have increased from 41.3 days to 74.2 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 30 | 67 | 80 | 98 | 148 | |
| 24 | 60 | 68 | 82 | 134 | |
| Operating Profit | 6 | 7 | 12 | 15 | 14 |
| OPM % | 19% | 11% | 15% | 16% | 9% |
| 0 | 0 | 0 | 0 | 1 | |
| Interest | 2 | 2 | 3 | 4 | 3 |
| Depreciation | 4 | 4 | 4 | 5 | 5 |
| Profit before tax | 1 | 1 | 5 | 7 | 6 |
| Tax % | 57% | 39% | 24% | 24% | 20% |
| 0 | 1 | 4 | 5 | 5 | |
| EPS in Rs | 0.33 | 0.88 | 5.36 | 6.93 | 4.30 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 30% |
| TTM: | 51% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 97% |
| TTM: | -16% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 103% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 19% |
| 3 Years: | 22% |
| Last Year: | 12% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 4 | 4 | 8 | 8 | 11 |
| Reserves | 3 | 4 | 4 | 11 | 47 |
| 30 | 36 | 42 | 53 | 43 | |
| 16 | 20 | 26 | 32 | 46 | |
| Total Liabilities | 53 | 64 | 81 | 103 | 146 |
| 21 | 21 | 22 | 26 | 31 | |
| CWIP | 0 | 0 | 2 | 4 | 8 |
| Investments | 0 | 0 | 0 | 0 | 6 |
| 32 | 44 | 57 | 73 | 101 | |
| Total Assets | 53 | 64 | 81 | 103 | 146 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| -5 | -1 | 8 | 9 | -14 | |
| -3 | -3 | -8 | -11 | -20 | |
| 8 | 4 | -0 | 2 | 34 | |
| Net Cash Flow | -0 | 0 | -1 | -0 | 0 |
| Free Cash Flow | -8 | -4 | 0 | -2 | -28 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | -75% | -9% | 71% | 70% | -88% |
Ratios
Standalone / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 235 | 104 | 116 | 142 | 129 |
| Inventory Days | 136 | 121 | 161 | 161 | 125 |
| Days Payable | 273 | 128 | 149 | 144 | 150 |
| Cash Conversion Cycle | 98 | 97 | 128 | 159 | 103 |
| Working Capital Days | 98 | 33 | 28 | 22 | 74 |
| ROCE % | 8% | 17% | 17% | 11% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Cosmetics Capacity Utilization - Creams % |
|
||
| Cosmetics Monthly Production Volume - Creams Million units/month |
|||
| Export Revenue as % of Total Revenue % |
|||
| Own Brand Sales as % of Total Revenue % |
|||
| Pharma Capacity Utilization - Tablets % |
|||
| Pharma Monthly Production Volume - Tablets Million units/month |
|||
| Pharmaceuticals Revenue as % of Total Revenue % |
|||
| Top 5 Customer Concentration % of revenue |
|||
Extracted by Screener AI
Documents
Announcements
-
Intimation Regarding Change In The Corporate Identification Number (CIN) Of The Company Consequent Upon Alteration Of The Object Clause Of The Memorandum Of Association
- MCA registered revised CIN after AGM-approved alteration of object clause on 9 October 2026.
-
Incorporation Of Proposed Subsidiary- Longevity Science Private Limited
- Astonea Labs incorporated Longevity Science Pvt Ltd on 8 Oct 2026; plans 51% subscription for Rs5.1 lakh.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Submitted Regulation 74(5) certificate for quarter ended 30 September 2026; no demat/remat requests received.
- Closure of Trading Window
- Resubmission Of Financial Results For The Half Year Ended 31.03.2025 In Response To BSE Communication
Business Overview[1]
Astonea Labs is a healthcare and pharmaceutical company with capabilities across pharmaceutical manufacturing, contract development and manufacturing, and cosmetic and personal care manufacturing. Its operations are supported by R&D capabilities, scientific expertise, manufacturing infrastructure and quality systems, serving both domestic and international markets.